Cantor Fitzgerald set a $74.00 target price on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report report published on Tuesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

ANIP has been the topic of several other research reports. BidaskClub downgraded shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, August 1st. Zacks Investment Research downgraded shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 10th. ValuEngine downgraded shares of ANI Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, September 12th. Finally, Canaccord Genuity set a $75.00 price target on shares of ANI Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, August 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. ANI Pharmaceuticals presently has an average rating of Hold and a consensus target price of $71.00.

Shares of NASDAQ:ANIP traded down $1.38 during midday trading on Tuesday, reaching $52.66. 78,559 shares of the company were exchanged, compared to its average volume of 73,741. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.89 and a current ratio of 3.34. ANI Pharmaceuticals has a one year low of $48.40 and a one year high of $74.70. The firm has a market cap of $653.68 million, a price-to-earnings ratio of 14.59 and a beta of 2.64.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $1.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.17 by $0.12. The firm had revenue of $50.70 million during the quarter, compared to analyst estimates of $50.97 million. ANI Pharmaceuticals had a net margin of 0.23% and a return on equity of 28.39%. ANI Pharmaceuticals’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.11 earnings per share. As a group, research analysts predict that ANI Pharmaceuticals will post 4.49 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the stock. Teachers Retirement System of The State of Kentucky increased its stake in ANI Pharmaceuticals by 99.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 2,005 shares of the specialty pharmaceutical company’s stock worth $113,000 after buying an additional 1,000 shares during the period. Bessemer Group Inc. purchased a new position in ANI Pharmaceuticals in the 3rd quarter worth about $138,000. Piedmont Investment Advisors LLC purchased a new position in ANI Pharmaceuticals in the 2nd quarter worth about $140,000. Truvestments Capital LLC purchased a new position in ANI Pharmaceuticals in the 3rd quarter worth about $152,000. Finally, Stifel Financial Corp purchased a new position in ANI Pharmaceuticals in the 1st quarter worth about $215,000. 61.10% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

See Also: Outstanding Shares

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.